PMID- 25026432
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20210526
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 92
IP  - 8
DP  - 2014 Aug
TI  - The effect of neuropeptide Y on cell survival and neurotrophin expression in 
      in-vitro models of Alzheimer's disease.
PG  - 621-30
LID - 10.1139/cjpp-2014-0099 [doi]
AB  - Alzheimer's disease (AD) is a disorder characterized by the accumulation of 
      abnormally folded protein fragments in neurons, i.e., beta-amyloid (Abeta) and tau 
      protein, leading to cell death. Several neuropeptides present in the central 
      nervous system (CNS) are believed to be involved in the pathophysiology of AD. 
      Among them, neuropeptide Y (NPY), a small peptide widely distributed throughout 
      the brain, has generated interest because of its role in neuroprotection against 
      excitotoxicity in animal models of AD. In addition, it has been shown that NPY 
      modulates neurogenesis. Interestingly, these latter effects are similar to those 
      elicited by neurotrophins, which are critical molecules for the function and 
      survival of neurons that degenerate during the course of AD. In this review we 
      summarize the evidence for the involvement of NPY and neurotrophins in AD 
      pathogenesis, and the similarity between them in CNS neurons. Finally, we 
      recapitulate our recent in-vitro evidence for the involvement of neurotrophin 
      nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the 
      neuroprotective effect elicited by NPY in AD neuron-like models (neuroblastoma 
      cells or primary cultures exposed to toxic concentrations of Abeta's pathogenic 
      fragment 25-35), and propose a putative mechanism based on NPY-induced inhibition 
      of voltage-dependent Ca(2+) influx in pre- and post-synaptic neurons.
FAU - Angelucci, Francesco
AU  - Angelucci F
AD  - a Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 
      Via Ardeatina 354, 00142 Rome, Italy.
FAU - Gelfo, Francesca
AU  - Gelfo F
FAU - Fiore, Marco
AU  - Fiore M
FAU - Croce, Nicoletta
AU  - Croce N
FAU - Mathe, Aleksander A
AU  - Mathe AA
FAU - Bernardini, Sergio
AU  - Bernardini S
FAU - Caltagirone, Carlo
AU  - Caltagirone C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140613
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Calcium Channels)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neuropeptide Y)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Alzheimer Disease/*metabolism/pathology
MH  - Amyloid beta-Peptides/metabolism
MH  - Animals
MH  - Calcium Channels/metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival
MH  - Humans
MH  - Nerve Growth Factors/*genetics/metabolism
MH  - Neurons/drug effects/metabolism/pathology
MH  - Neuropeptide Y/*metabolism/pharmacology
MH  - Neuroprotective Agents/pharmacology
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - amyloid beta
OT  - amyloide beta
OT  - brain-derived neurotrophic factor
OT  - facteur BNDF
OT  - facteur neuronal NGF
OT  - in vitro models
OT  - maladie d'Alzheimer
OT  - modeles in vitro
OT  - nerve growth factor
OT  - neuropeptide Y
OT  - neuroprotection
OT  - neurotrophines
OT  - neurotrophins
EDAT- 2014/07/16 06:00
MHDA- 2015/05/12 06:00
CRDT- 2014/07/16 06:00
PHST- 2014/07/16 06:00 [entrez]
PHST- 2014/07/16 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - 10.1139/cjpp-2014-0099 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2014 Aug;92(8):621-30. doi: 10.1139/cjpp-2014-0099. Epub 
      2014 Jun 13.